Relationship between long-term use of antimicrobial agent and risk of kidney cancer_West China Medical Journal

Authors：

LIU Jiani ^1,2 , CHEN Xiangyu ² ,  DAI Xiaoyu ^2,3

1. School of Clinical Medicine, North Sichuan Medical College, Nanchong, Sichuan 637100, P. R. China;
2. Department of Nephrology, Mianyang Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang Central Hospital, Mianyang, Sichuan 621000, P. R. China;
3. Jiange People’s Hospital, Guangyuan, Sichuan 628399, P. R. China;

Corresponding author：

DAI Xiaoyu, Email: daixy001@163.com

Keywords：

Antimicrobial agent; kidney cancer; mechanism

DOI：

10.7507/1002-0179.202406255

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Renal cancer is a common malignant tumor and the deadliest cancer of the urinary and reproductive system. Given the increasing incidence rate of kidney cancer, timely intervention of its controllable risk factors is crucial. Antimicrobial agent is widely used worldwide, and in recent years, some studies have found that long-term use of antimicrobial agent is associated with an increased risk of kidney cancer. The mechanism may involve multiple factors such as nephrotoxicity of antimicrobial agent and intestinal flora imbalance. This article reviews the relationship between long-term use of antimicrobial agent and risk of kidney cancer, and explores possible mechanisms, to understand the impact of long-term use of antimicrobial agent on the risk of kidney cancer, and to provide more references for early prevention of kidney cancer and rational use of antimicrobial agent.

Citation： LIU Jiani, CHEN Xiangyu, DAI Xiaoyu. Relationship between long-term use of antimicrobial agent and risk of kidney cancer. West China Medical Journal, 2024, 39(8): 1319-1322. doi: 10.7507/1002-0179.202406255 Copy

1.	Capitanio U, Bensalah K, Bex A, et al. Epidemiology of renal cell carcinoma. Eur Urol, 2019, 75(1): 74-84.
2.	Bahadoram S, Davoodi M, Hassanzadeh S, et al. Renal cell carcinoma: an overview of the epidemiology, diagnosis, and treatment. G Ital Nefrol, 2022, 39(3): 39.
3.	Gray RE, Harris GT. Renal cell carcinoma: diagnosis and management. Am Fam Physician, 2019, 99(3): 179-184.
4.	Huang J, Leung DK, Chan EO, et al. A global trend analysis of kidney cancer incidence and mortality and their associations with smoking, alcohol consumption, and metabolic syndrome. Eur Urol Focus, 2022, 8(1): 200-209.
5.	王红心, 樊文龙, 杨晓雨, 等. 亚洲五个国家和地区肾癌负担趋势分析与预测. 华南预防医学, 2023, 49(1): 1-4, 9.
6.	Wang Z, Wang L, Wang S, et al. Burden of kidney cancer and attributed risk factors in China from 1990 to 2019. Front Public Health, 2022, 10: 1062504.
7.	Scelo G, Larose TL. Epidemiology and risk factors for kidney cancer. J Clin Oncol, 2018, 36(36): JCO2018791905.
8.	Baran A, Kwiatkowska A, Potocki L. Antibiotics and bacterial resistance-a short story of an endless arms race. Int J Mol Sci, 2023, 24(6): 5777.
9.	Principi N, Esposito S. Antibiotic-related adverse events in paediatrics: unique characteristics. Expert Opin Drug Saf, 2019, 18(9): 795-802.
10.	Park SJ, Hong J, Park YJ, et al. Association between antibiotic use and subsequent risk of prostate cancer: a retrospective cohort study in South Korea. Int J Urol, 2024, 31(4): 325-331.
11.	Ternák G, Berényi K, Sümegi A, et al. Antibiotic consumption patterns in european countries may be associated with the incidence of major carcinomas. Antibiotics (Basel), 2020, 9(10): 643.
12.	Sergentanis TN, Zagouri F, Zografos GC. Is antibiotic use a risk factor for breast cancer? A meta-analysis. Pharmacoepidemiol Drug Saf, 2010, 19(11): 1101-1107.
13.	Cao Y, Wu K, Mehta R, et al. Long-term use of antibiotics and risk of colorectal adenoma. Gut, 2018, 67(4): 672-678.
14.	Kim M, Park SJ, Choi S, et al. Association of antibiotic use with risk of lung cancer: a nationwide cohort study. J Infect Public Health, 2023, 16(7): 1123-1130.
15.	Kilkkinen A, Rissanen H, Klaukka T, et al. Antibiotic use predicts an increased risk of cancer. Int J Cancer, 2008, 123(9): 2152-2155.
16.	Boursi B, Mamtani R, Haynes K, et al. Recurrent antibiotic exposure may promote cancer formation--Another step in understanding the role of the human microbiota?. Eur J Cancer, 2015, 51(17): 2655-2664.
17.	Petrelli F, Ghidini M, Ghidini A, et al. Use of antibiotics and risk of cancer: a systematic review and meta-analysis of observational studies. Cancers (Basel), 2019, 11(8): 1174.
18.	蔡琰, 腊岩, 高岩. β-内酰胺类抗生素肾损害及抗生素脑病. 国外医药(抗生素分册), 2011, 32(1): 38-42.
19.	Alhassani RY, Bagadood RM, Balubaid RN, et al. Drug therapies affecting renal function: an overview. Cureus, 2021, 13(11): e19924.
20.	何威逊, 杨友. 抗生素与肾损害. 临床儿科杂志, 2005, 23(12): 882-884.
21.	Campbell RE, Chen CH, Edelstein CL. Overview of antibiotic-induced nephrotoxicity. Kidney Int Rep, 2023, 8(11): 2211-2225.
22.	Lu J, Azad MAK, Moreau JLM, et al. Inwardly rectifying potassium channels mediate polymyxin-induced nephrotoxicity. Cell Mol Life Sci, 2022, 79(6): 296.
23.	Yang J, Ko YS, Lee HY, et al. Mechanisms of piperacillin/tazobactam nephrotoxicity: piperacillin/tazobactam-induced direct tubular damage in mice. Antibiotics (Basel), 2023, 12(7): 1121.
24.	Blair M, Côté JM, Cotter A, et al. Nephrotoxicity from vancomycin combined with piperacillin-tazobactam: a comprehensive review. Am J Nephrol, 2021, 52(2): 85-97.
25.	Yeh TH, Tu KC, Wang HY, et al. From acute to chronic: unraveling the pathophysiological mechanisms of the progression from acute kidney injury to acute kidney disease to chronic kidney disease. Int J Mol Sci, 2024, 25(3): 1755.
26.	Horne KL, Packington R, Monaghan J, et al. Three-year outcomes after acute kidney injury: results of a prospective parallel group cohort study. BMJ Open, 2017, 7(3): e015316.
27.	Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int, 2012, 81(5): 442-448.
28.	Saly DL, Eswarappa MS, Street SE, et al. Renal cell cancer and chronic kidney disease. Adv Chronic Kidney Dis, 2021, 28(5): 460-468.e1.
29.	Lin CW, Zheng JQ, Tzou KY, et al. Influenza vaccination is associated with lower risk of renal cell carcinoma among chronic kidney disease patients: a population-based cohort study. Clin Kidney J, 2023, 16(11): 1936-1946.
30.	Hu M, Wang Q, Liu B, et al. Chronic kidney disease and cancer: inter-relationships and mechanisms. Front Cell Dev Biol, 2022, 10: 868715.
31.	DiMaio D, Emu B, Goodman AL, et al. Cancer microbiology. J Natl Cancer Inst, 2022, 114(5): 651-663.
32.	施旭, 冯德超, 李登雄, 等. 代谢综合征和肾癌的研究进展. 临床泌尿外科杂志, 2022, 37(9): 712-717.
33.	Wilkins AT, Reimer RA. Obesity, early life gut microbiota, and antibiotics. Microorganisms, 2021, 9(2): 413.
34.	Ianiro G, Tilg H, Gasbarrini A. Antibiotics as deep modulators of gut microbiota: between good and evil. Gut, 2016, 65(11): 1906-1915.
35.	Vandenplas Y, Carnielli VP, Ksiazyk J, et al. Factors affecting early-life intestinal microbiota development. Nutrition, 2020, 78: 110812.
36.	Evenepoel P, Poesen R, Meijers B. The gut-kidney axis. Pediatr Nephrol, 2017, 32(11): 2005-2014.
37.	于晓倩, 姜月华, 赵世腾, 等. 肠道菌群失调与血管内皮损伤的相关机制研究概况. 中国现代医学杂志, 2024, 34(5): 37-43.
38.	Ferraro PM, Curhan GC, Gambaro G, et al. Antibiotic use and risk of incident kidney stones in female nurses. Am J Kidney Dis, 2019, 74(6): 736-741.
39.	Daudon M, Jungers P. Drug-induced renal calculi: epidemiology, prevention and management. Drugs, 2004, 64(3): 245-275.
40.	Gupta S, Singh Kanwar S. The influence of dysbiosis on kidney stones that risk up renal cell carcinoma (RCC). Semin Cancer Biol, 2021, 70: 134-138.
41.	Cheungpasitporn W, Thongprayoon C, O’Corragain OA, et al. The risk of kidney cancer in patients with kidney stones: a systematic review and meta-analysis. QJM, 2015, 108(3): 205-212.
42.	Goldman P. Metronidazole: proven benefits and potential risks. Johns Hopkins Med J, 1980, 147(1): 1-9.
43.	Dees JH, Heatfield BM, Reuber MD, et al. Adenocarcinoma of the kidney. III. Histogenesis of renal adenocarcinomas induced in rats by N-(4’-fluoro-4-biphenylyl)acetamide. J Natl Cancer Inst, 1980, 64(6): 1537-1545.
44.	Dees JH, Reuber MD, Trump BF. Adenocarcinoma of the kidney. I. Ultrastructure of renal adenocarcinomas induced in rats by N-(4’-fluoro-4-biphenylyl)acetamide. J Natl Cancer Inst, 1976, 57(4): 779-794.
45.	Bao C, Wang K, Ding Y, et al. Association between anti-bacterial drug use and digestive system neoplasms: a systematic review and meta-analysis. Front Oncol, 2019, 9: 1298.
46.	Pisonero-Vaquero S, Medina DL. Lysosomotropic drugs: pharmacological tools to study lysosomal function. Curr Drug Metab, 2017, 18(12): 1147-1158.

1. Capitanio U, Bensalah K, Bex A, et al. Epidemiology of renal cell carcinoma. Eur Urol, 2019, 75(1): 74-84.
2. Bahadoram S, Davoodi M, Hassanzadeh S, et al. Renal cell carcinoma: an overview of the epidemiology, diagnosis, and treatment. G Ital Nefrol, 2022, 39(3): 39.
3. Gray RE, Harris GT. Renal cell carcinoma: diagnosis and management. Am Fam Physician, 2019, 99(3): 179-184.
4. Huang J, Leung DK, Chan EO, et al. A global trend analysis of kidney cancer incidence and mortality and their associations with smoking, alcohol consumption, and metabolic syndrome. Eur Urol Focus, 2022, 8(1): 200-209.
5. 王红心, 樊文龙, 杨晓雨, 等. 亚洲五个国家和地区肾癌负担趋势分析与预测. 华南预防医学, 2023, 49(1): 1-4, 9.
6. Wang Z, Wang L, Wang S, et al. Burden of kidney cancer and attributed risk factors in China from 1990 to 2019. Front Public Health, 2022, 10: 1062504.
7. Scelo G, Larose TL. Epidemiology and risk factors for kidney cancer. J Clin Oncol, 2018, 36(36): JCO2018791905.
8. Baran A, Kwiatkowska A, Potocki L. Antibiotics and bacterial resistance-a short story of an endless arms race. Int J Mol Sci, 2023, 24(6): 5777.
9. Principi N, Esposito S. Antibiotic-related adverse events in paediatrics: unique characteristics. Expert Opin Drug Saf, 2019, 18(9): 795-802.
10. Park SJ, Hong J, Park YJ, et al. Association between antibiotic use and subsequent risk of prostate cancer: a retrospective cohort study in South Korea. Int J Urol, 2024, 31(4): 325-331.
11. Ternák G, Berényi K, Sümegi A, et al. Antibiotic consumption patterns in european countries may be associated with the incidence of major carcinomas. Antibiotics (Basel), 2020, 9(10): 643.
12. Sergentanis TN, Zagouri F, Zografos GC. Is antibiotic use a risk factor for breast cancer? A meta-analysis. Pharmacoepidemiol Drug Saf, 2010, 19(11): 1101-1107.
13. Cao Y, Wu K, Mehta R, et al. Long-term use of antibiotics and risk of colorectal adenoma. Gut, 2018, 67(4): 672-678.
14. Kim M, Park SJ, Choi S, et al. Association of antibiotic use with risk of lung cancer: a nationwide cohort study. J Infect Public Health, 2023, 16(7): 1123-1130.
15. Kilkkinen A, Rissanen H, Klaukka T, et al. Antibiotic use predicts an increased risk of cancer. Int J Cancer, 2008, 123(9): 2152-2155.
16. Boursi B, Mamtani R, Haynes K, et al. Recurrent antibiotic exposure may promote cancer formation--Another step in understanding the role of the human microbiota?. Eur J Cancer, 2015, 51(17): 2655-2664.
17. Petrelli F, Ghidini M, Ghidini A, et al. Use of antibiotics and risk of cancer: a systematic review and meta-analysis of observational studies. Cancers (Basel), 2019, 11(8): 1174.
18. 蔡琰, 腊岩, 高岩. β-内酰胺类抗生素肾损害及抗生素脑病. 国外医药(抗生素分册), 2011, 32(1): 38-42.
19. Alhassani RY, Bagadood RM, Balubaid RN, et al. Drug therapies affecting renal function: an overview. Cureus, 2021, 13(11): e19924.
20. 何威逊, 杨友. 抗生素与肾损害. 临床儿科杂志, 2005, 23(12): 882-884.
21. Campbell RE, Chen CH, Edelstein CL. Overview of antibiotic-induced nephrotoxicity. Kidney Int Rep, 2023, 8(11): 2211-2225.
22. Lu J, Azad MAK, Moreau JLM, et al. Inwardly rectifying potassium channels mediate polymyxin-induced nephrotoxicity. Cell Mol Life Sci, 2022, 79(6): 296.
23. Yang J, Ko YS, Lee HY, et al. Mechanisms of piperacillin/tazobactam nephrotoxicity: piperacillin/tazobactam-induced direct tubular damage in mice. Antibiotics (Basel), 2023, 12(7): 1121.
24. Blair M, Côté JM, Cotter A, et al. Nephrotoxicity from vancomycin combined with piperacillin-tazobactam: a comprehensive review. Am J Nephrol, 2021, 52(2): 85-97.
25. Yeh TH, Tu KC, Wang HY, et al. From acute to chronic: unraveling the pathophysiological mechanisms of the progression from acute kidney injury to acute kidney disease to chronic kidney disease. Int J Mol Sci, 2024, 25(3): 1755.
26. Horne KL, Packington R, Monaghan J, et al. Three-year outcomes after acute kidney injury: results of a prospective parallel group cohort study. BMJ Open, 2017, 7(3): e015316.
27. Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int, 2012, 81(5): 442-448.
28. Saly DL, Eswarappa MS, Street SE, et al. Renal cell cancer and chronic kidney disease. Adv Chronic Kidney Dis, 2021, 28(5): 460-468.e1.
29. Lin CW, Zheng JQ, Tzou KY, et al. Influenza vaccination is associated with lower risk of renal cell carcinoma among chronic kidney disease patients: a population-based cohort study. Clin Kidney J, 2023, 16(11): 1936-1946.
30. Hu M, Wang Q, Liu B, et al. Chronic kidney disease and cancer: inter-relationships and mechanisms. Front Cell Dev Biol, 2022, 10: 868715.
31. DiMaio D, Emu B, Goodman AL, et al. Cancer microbiology. J Natl Cancer Inst, 2022, 114(5): 651-663.
32. 施旭, 冯德超, 李登雄, 等. 代谢综合征和肾癌的研究进展. 临床泌尿外科杂志, 2022, 37(9): 712-717.
33. Wilkins AT, Reimer RA. Obesity, early life gut microbiota, and antibiotics. Microorganisms, 2021, 9(2): 413.
34. Ianiro G, Tilg H, Gasbarrini A. Antibiotics as deep modulators of gut microbiota: between good and evil. Gut, 2016, 65(11): 1906-1915.
35. Vandenplas Y, Carnielli VP, Ksiazyk J, et al. Factors affecting early-life intestinal microbiota development. Nutrition, 2020, 78: 110812.
36. Evenepoel P, Poesen R, Meijers B. The gut-kidney axis. Pediatr Nephrol, 2017, 32(11): 2005-2014.
37. 于晓倩, 姜月华, 赵世腾, 等. 肠道菌群失调与血管内皮损伤的相关机制研究概况. 中国现代医学杂志, 2024, 34(5): 37-43.
38. Ferraro PM, Curhan GC, Gambaro G, et al. Antibiotic use and risk of incident kidney stones in female nurses. Am J Kidney Dis, 2019, 74(6): 736-741.
39. Daudon M, Jungers P. Drug-induced renal calculi: epidemiology, prevention and management. Drugs, 2004, 64(3): 245-275.
40. Gupta S, Singh Kanwar S. The influence of dysbiosis on kidney stones that risk up renal cell carcinoma (RCC). Semin Cancer Biol, 2021, 70: 134-138.
41. Cheungpasitporn W, Thongprayoon C, O’Corragain OA, et al. The risk of kidney cancer in patients with kidney stones: a systematic review and meta-analysis. QJM, 2015, 108(3): 205-212.
42. Goldman P. Metronidazole: proven benefits and potential risks. Johns Hopkins Med J, 1980, 147(1): 1-9.
43. Dees JH, Heatfield BM, Reuber MD, et al. Adenocarcinoma of the kidney. III. Histogenesis of renal adenocarcinomas induced in rats by N-(4’-fluoro-4-biphenylyl)acetamide. J Natl Cancer Inst, 1980, 64(6): 1537-1545.
44. Dees JH, Reuber MD, Trump BF. Adenocarcinoma of the kidney. I. Ultrastructure of renal adenocarcinomas induced in rats by N-(4’-fluoro-4-biphenylyl)acetamide. J Natl Cancer Inst, 1976, 57(4): 779-794.
45. Bao C, Wang K, Ding Y, et al. Association between anti-bacterial drug use and digestive system neoplasms: a systematic review and meta-analysis. Front Oncol, 2019, 9: 1298.
46. Pisonero-Vaquero S, Medina DL. Lysosomotropic drugs: pharmacological tools to study lysosomal function. Curr Drug Metab, 2017, 18(12): 1147-1158.

Previous Article
Research progress of fetuin B and coronary artery disease
Next Article
Application of compound Huangbai liquid coating agent in burn treatment

West China Medical Journal

Relationship between long-term use of antimicrobial agent and risk of kidney cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content